Literature DB >> 8456277

Ablation of transplanted HTLV-I tax-transformed tumors in mice by antisense inhibition of NF-kappa B.

I Kitajima, T Shinohara, J Bilakovics, D A Brown, X Xu, M Nerenberg.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8456277     DOI: 10.1126/science.8456277

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  8 in total

1.  Inhibition of IL-6 in mice by anti-NF-kappaB oligodeoxyribonucleotide N3'-->oligodeoxyribonnucleotide N3' --> P5' phosphoramidates.

Authors:  L Wang; S Gryaznov; M Nerenberg
Journal:  Inflammation       Date:  1999-12       Impact factor: 4.092

Review 2.  Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents.

Authors:  W Brysch; K H Schlingensiepen
Journal:  Cell Mol Neurobiol       Date:  1994-10       Impact factor: 5.046

3.  Role of post-translational modifications of HTLV-1 Tax in NF-κB activation.

Authors:  Noula Shembade; Edward W Harhaj
Journal:  World J Biol Chem       Date:  2010-01-26

4.  Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides.

Authors:  C Beltinger; H U Saragovi; R M Smith; L LeSauteur; N Shah; L DeDionisio; L Christensen; A Raible; L Jarett; A M Gewirtz
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 5.  Anti-apoptotic effect of Tax: an NF-κB path or a CREB way?

Authors:  Daniela Saggioro
Journal:  Viruses       Date:  2011-06-27       Impact factor: 5.048

Review 6.  Regulation of HTLV-1 tax stability, cellular trafficking and NF-κB activation by the ubiquitin-proteasome pathway.

Authors:  Alfonso Lavorgna; Edward William Harhaj
Journal:  Viruses       Date:  2014-10-23       Impact factor: 5.048

Review 7.  The intricate interplay between RNA viruses and NF-κB.

Authors:  M Lienhard Schmitz; Michael Kracht; Vera V Saul
Journal:  Biochim Biophys Acta       Date:  2014-08-10

Review 8.  Antisense oligonucleotide therapy for urologic tumors.

Authors:  Ingo Kausch; Andreas Böhle
Journal:  Curr Urol Rep       Date:  2003-02       Impact factor: 2.862

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.